News

Lipocine previously announced positive top line efficacy from the SOAR clinical study in September 2014 and expects to announce top-line results from the 52 week safety assessment portion

I-STAR technology can rapidly screen antibodies from survivors of Ebola to uncover those with exceptional biologic activity that may lead to the development of a therapeutic antibody. BVGH,

This process was successfully conducted by the Vancouver Commodities Group (VCG) that had been hired by Nutra Pharma to begin the process of identifying and vetting potential distributors

The targeted enrollment has been achieved in both patient cohorts of the Phase 3 NOVA trial of niraparib, and TESARO expects data from NOVA in the fourth quarter

Scheduled to be completed by January 2017, the new facility is claimed to be the largest mammalian cell culture manufacturing facility using disposable bioreactors in the world. The

The joint research is funded by a grant from CurePSP, a nonprofit organization, which will support the collection and analysis of exome sequencing data from more than 700

Discovered and developed by Lycera based on technology licensed from the University of Michigan, LYC-30937 is designed to selectively induce cell death (apoptosis) in disease-causing immune cells, sparing

The AR-12 orphan drug status was based on application packages that included relevant data from pre-clinical models for each condition. In the application regarding cryptococcosis, results of an

Breo is a fixed-dose combination of fluticasone furoate (FF) and vilanterol (VI) and two strengths, 100/25mcg and 200/25mcg of the combination have been approved in the US for